TABLE 1.

Clinical Characteristics of Study Cohort

	CD (n = 157)	UC (n = 31)	P
Male gender, n (%)	81 (52)	12 (39)	0.20
Median (IQR) age at diagnosis (yr)	11 (8–13)	12 (9–14)	0.80
Median (IQR) duration of disease at the time of IFX induction (mo)	11 (4–30)	17 (6–27)	0.45
Median (IQR) age at IFX induction (yr)	13 (10–15)	14 (10–15)	0.85
Primary indication for IFX, n (%)
First line therapy	24 (15)	2 (6)	0.15
Intolerant or failed immunomodulator	111 (71)	16 (52)	0.08
Steroid refractory	22 (14)	13 (42)	0.0007
Immunomodulator use before IFX induction, n (%)
Thiopurines	104 (66)	17 (55)	0.37
MTX	3 (2)	0	0.42
Median (IQR) duration of immunomodulator before IFX induction (mo)	10.8 (6–24)	12.8 (7–19)	0.67
Immunomodulator at the time of IFX induction, n (%)
None	55 (35)	20 (65)	0.007
Thiopurines	33 (21)	9 (29)	0.22
MTX	69 (44)	2 (6)	0.08
Steroid use during IFX induction, n (%)	57 (36)	20 (65)	0.004
Median (IQR) duration of disease at the last follow-up (mo)	60 (35–90)	47 (32–57)	0.04
Median (IQR) duration of IFX at the last follow-up (mo)	30 (17–51)	25 (15–34)	0.05